RxDoctor Payments DataLook up a doctor →

Sandra Estrada

Nurse Practitioner · Silverdale, WANPI 1427082833

Payments from drug & device makers

$12,471in general payments, 2019–2025

Across 479 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • AbbVie$681
  • EMD Serono, Inc.$659
  • Novartis$643
  • Lilly USA, LLC$485
  • Pfizer$482
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$180%
  • Travel & lodging$1,80614%
  • Food & beverage$10,54785%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,471 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$161,978
Medicare patients
204
Services billed
19,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate12$105,960
Nurtec OdtRimegepant Sulfate51$66,452
Emgality PenGalcanezumab-Gnlm70$56,747
XcopriCenobamate39$48,426
GlatopaGlatiramer Acetate20$44,904
BriviactBrivaracetam22$31,711
Aimovig AutoinjectorErenumab-Aooe27$20,314
KeppraLevetiracetam13$18,936
Glatiramer Acetate13$18,406
FycompaPerampanel13$16,423
Ajovy AutoinjectorFremanezumab-Vfrm11$15,999
VimpatLacosamide11$15,859
UbrelvyUbrogepant15$15,825
QuliptaAtogepant12$13,646
Levetiracetam277$10,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$159$105,96012 claims
PfizerNurtec Odt$482$66,45251 claims
SK Life Science, Inc.Xcopri$287$48,42639 claims
UCB, Inc.Briviact, Vimpat$257$47,57033 claims
AbbVieUbrelvy, Qulipta$681$29,47127 claims
Eisai Inc.Fycompa$137$16,42313 claims
Upsher-smith Laboratories LLCTopiramate$120$1,363122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →